PTGS2 and breast carcinoma: In conclusion, COX-2 might have a role in breast cancer dormancy but its targeting with selective COX-2 inhibitors has not achieved the expected results, probably due to a pathway redundancy in the inflammatory cascades that limits the efficacy of a mono-target drug.